Equillium, Inc. (EQ) reporting calendar
Equillium, Inc. files periodic reports with the SEC as EQ on Nasdaq. Atlas tracks 31 filed reports for this issuer, each linked to its original EDGAR accession.
- Next window
- 21 Jul 2026 – 5 Sep 2026
- Latest report
- 10-Q
- Period ended
- 31 Mar 2026
- Filed
- 13 May 2026
- Reports on record
- 31
How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 44 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.
Open EQ market profile
Latest filing on SEC EDGAR ↗
Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates
Filed periodic reports
| Form | Period ended | Filed | Lag | SEC accession |
|---|---|---|---|---|
| 10-Q | 31 Mar 2026 | 13 May 2026 | 43 days | 0001193125-26-221625 |
| 10-K | 31 Dec 2025 | 25 Mar 2026 | 84 days | 0001193125-26-124143 |
| 10-Q | 30 Sep 2025 | 13 Nov 2025 | 44 days | 0001193125-25-280202 |
| 10-Q | 30 Jun 2025 | 14 Aug 2025 | 45 days | 0000950170-25-108834 |
| 10-Q | 31 Mar 2025 | 14 May 2025 | 44 days | 0000950170-25-071389 |
| 10-K | 31 Dec 2024 | 27 Mar 2025 | 86 days | 0000950170-25-045726 |
| 10-Q | 30 Sep 2024 | 13 Nov 2024 | 44 days | 0000950170-24-126322 |
| 10-Q | 30 Jun 2024 | 8 Aug 2024 | 39 days | 0000950170-24-093949 |
| 10-Q | 31 Mar 2024 | 9 May 2024 | 39 days | 0000950170-24-056960 |
| 10-K | 31 Dec 2023 | 25 Mar 2024 | 85 days | 0000950170-24-035919 |
| 10-Q | 30 Sep 2023 | 8 Nov 2023 | 39 days | 0000950170-23-061108 |
| 10-Q | 30 Jun 2023 | 9 Aug 2023 | 40 days | 0000950170-23-040583 |
| 10-Q | 31 Mar 2023 | 11 May 2023 | 41 days | 0000950170-23-021236 |
| 10-K | 31 Dec 2022 | 23 Mar 2023 | 82 days | 0000950170-23-009492 |
| 10-Q | 30 Sep 2022 | 14 Nov 2022 | 45 days | 0000950170-22-025052 |
| 10-Q | 30 Jun 2022 | 15 Aug 2022 | 46 days | 0000950170-22-017399 |
| 10-Q | 31 Mar 2022 | 12 May 2022 | 42 days | 0000950170-22-009669 |
| 10-K | 31 Dec 2021 | 23 Mar 2022 | 82 days | 0000950170-22-004407 |
| 10-Q | 30 Sep 2021 | 10 Nov 2021 | 41 days | 0000950170-21-004079 |
| 10-Q | 30 Jun 2021 | 10 Aug 2021 | 41 days | 0000950170-21-001180 |
| 10-Q | 31 Mar 2021 | 13 May 2021 | 43 days | 0000950170-21-000224 |
| 10-K | 31 Dec 2020 | 24 Mar 2021 | 83 days | 0001564590-21-015103 |
| 10-Q | 30 Sep 2020 | 10 Nov 2020 | 41 days | 0001564590-20-052979 |
| 10-Q | 30 Jun 2020 | 12 Aug 2020 | 43 days | 0001564590-20-039503 |
| 10-Q | 31 Mar 2020 | 13 May 2020 | 43 days | 0001564590-20-025063 |
| 10-K | 31 Dec 2019 | 26 Mar 2020 | 86 days | 0001564590-20-013207 |
| 10-Q | 30 Sep 2019 | 12 Nov 2019 | 43 days | 0001564590-19-042933 |
| 10-Q | 30 Jun 2019 | 12 Aug 2019 | 43 days | 0001564590-19-031483 |
| 10-Q | 31 Mar 2019 | 13 May 2019 | 43 days | 0001564590-19-018839 |
| 10-K | 31 Dec 2018 | 27 Mar 2019 | 86 days | 0001564590-19-009580 |
| 10-Q | 30 Sep 2018 | 15 Nov 2018 | 46 days | 0001564590-18-029687 |
Source: SEC EDGAR company submissions for CIK 0001746466. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.